rss
Sex Transm Infect 2008;84:251 doi:10.1136/sti.2008.032755
  • Editorial

Government decision on national human papillomavirus vaccine programme is a sad day for sexual health

It is unbelievable! There we were in genitourinary medicine looking forward to the day in the not too distant future when we could actually complete a clinic and say “where have all the warts gone?” The Department of Health’s decision to go for Cervarix, which only contains human papillomavirus (HPV) types 16 and 18 as opposed to Gardasil, which contains 6, 11, 16 and 18 has shocked and appalled all of us working in sexual health. Here at last was a wonderful opportunity to make a major and lasting impact on one of the most common sexually transmitted infections in the United Kingdom. How could they have reached such a decision? All the science, all the trials, all the evidence showed both vaccines to be very effective at dealing with HPV 16 and 18 disease, but Gardasil …

Responses to this article

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.